Hosted on MSN8mon
Boehringer and Lilly report data from heart failure treatment trialData revealed a 10% relative decline in risk on the primary composite endpoint for participants treated with Jardiance compared to placebo, which did not reach statistical significance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback